The CRISP Trial IIB

A phase II trial of a colorectal cancer risk tool to optimize screening in primary care

Colorectal cancer is a major health problem in Australia. Despite this, many higher risk patients are not having colonoscopies when they should and many average risk patients are being over-screened with colonoscopies. The Phase IIB CRISP trial is a multi-site randomised controlled trial which aims to measure the efficacy of the CRISP ‘Colorectal cancer RISk Prediction tool’ on rates of ‘appropriate’ colorectal cancer screening when delivered in a standardised way by a research nurse in general practice. ‘Appropriate’ screening is defined as 1) no screening for people at average risk and younger than 50 years old, 2) screening with faecal occult blood test (‘iFOBT’) for people at average risk aged 50 and older, 3) colonoscopic screening for people at increased risk at any age, or 4) referral to a family cancer centre for people who are at potentially high risk at any age.

Current status:

Closed to recruitment; manuscript preparation

Publications:

Walker J, Macrae F, Winship I, Oberoi J, Saya S, Milton S et al. The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial. Trials. July 2018; 19:397

For more information contact:

Trial coordinator Dr. Jennifer Walker, Department of General Practice, The University of Melbourne (walker@unimelb.edu.au, +61 3 8559 7408)